Your browser doesn't support javascript.
loading
Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
Wei, Hui; Liu, Xueou; Wang, Ying; Lin, Dong; Zhou, Chunlin; Liu, Bingcheng; Qiu, Shaowei; Gu, Runxia; Li, Yan; Wei, Shuning; Gong, Benfa; Liu, Kaiqi; Gong, Xiaoyuan; Liu, Yuntao; Zhang, Guangji; Fang, Qiuyun; Zhang, Junping; Jin, Jingjing; Ma, Yueshen; Mi, Yingchang; Wang, Jianxiang.
Afiliação
  • Wei H; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; National Clinical Research Center for Blood Disease, Tianjin, China; Leukemia Center, Institute of Hematology an
  • Liu X; National Clinical Research Center for Blood Disease, Tianjin, China.
  • Wang Y; National Clinical Research Center for Blood Disease, Tianjin, China; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Lin D; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Zhou C; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Liu B; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Qiu S; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Gu R; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Li Y; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Wei S; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Gong B; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Liu K; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Gong X; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Liu Y; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Zhang G; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Fang Q; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Zhang J; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Jin J; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Ma Y; National Clinical Research Center for Blood Disease, Tianjin, China.
  • Mi Y; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; National Clinical Research Center for Blood Disease, Tianjin, China; Leukemia Center, Institute of Hematology an
  • Wang J; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; National Clinical Research Center for Blood Disease, Tianjin, China; Leukemia Center, Institute of Hematology an
Exp Hematol ; 96: 63-72.e3, 2021 04.
Article em En | MEDLINE | ID: mdl-33524443
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Neoplasia Residual / Subunidade alfa 2 de Fator de Ligação ao Core / Proteína 1 Parceira de Translocação de RUNX1 Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Exp Hematol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Neoplasia Residual / Subunidade alfa 2 de Fator de Ligação ao Core / Proteína 1 Parceira de Translocação de RUNX1 Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Exp Hematol Ano de publicação: 2021 Tipo de documento: Article